Aliso Viejo, Ca Headquarters

The next stage of research has therefore now begun at the highly specialized Analytical Research Laboratory

ALISO VIEJO, CA, UNITED STATES, August 25, 2022 /EINPresswire.com/ -- GenBio Inc is pleased to report a phenomenally successful conclusion to its first phase research into a rare natural extract when a new novel extraction procedure has been applied. The modified and more potent extract exceeded the scientists’ expectations. The next stage of research has therefore now begun at the highly specialized Analytical Research Laboratories, Southern Cross University, NSW Australia. The Analytical Research Laboratory (ARL) provides specialist capabilities in applied phytochemistry and can quickly identify the photoactivity and core compounds and molecules within the Company’s unique new extract and that may contribute more effectively to human health and will as well assist in the regulatory approval process. The company hopes to complete this work within two weeks and will keep the market informed of progress, and prior to commencing the next stage of research into purification and structural elucidation in Oxfordshire, UK

About GenBio, Inc.
GenBio, Inc. (https://genbioinc.com/) aims to create, through its IND Drug program, the next generation of anti-inflammatory drugs with the intention to disrupt the projected $191 billion+ anti-inflammatory drug market. GenBio, in addition, has access to a vast catalog of natural herbs, extracts, superfoods and functional food ingredients that can and will be formulated and licensed out to create a range of new nutraceuticals to aid in boosting the human immune system and promoting good health and longevity.

Forward Looking Statements
Statements in this press release about the future expectations, including without limitation, the likelihood that GenBio, Inc. will be able to meet minimum expectations, be successful and leverage capital markets to execute its growth strategy, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unexpected events, except as required by law. GenBio’s business strategy described in this press release is subject to innumerable risks, most significantly, whether the Company is successful in securing adequate financing. No information in this press release should be construed in any form, shape, or manner as an indication of the Company’s future revenues or financial condition.
Contact:

Todd D. Sonoga
GenBio Inc.
+1 949-705-8021
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

GenBio Inc